What did @drthierryjacquemin actually say?
Honestly, it's hard to say with any confidence. The transcript provided for this video is essentially incoherent, a garbled sequence of phrases that appears to be a failed auto-transcription of what was likely a Portuguese-language video. The caption mentions CJC-1295 and ipamorelin by name, and the hashtags confirm this is a peptide therapy promotional video, but no specific claims can be directly attributed to the creator from this transcript alone.
What we can work with: the video was posted by a physician ("medico" in the hashtags), has nearly 240,000 views, and is explicitly promoting these two growth hormone secretagogues to a general audience. That context alone warrants a close look at what's actually known about these compounds, and what physicians promoting them online sometimes get wrong.
Does the science back up common CJC-1295 and ipamorelin claims?
Partially, and only in narrow contexts. These are growth hormone secretagogues, meaning they stimulate the pituitary to release GH rather than introducing synthetic GH directly. That mechanism is real and documented.
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). Ipamorelin is a ghrelin mimetic and selective GH secretagogue. Research by Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) confirmed that CJC-1295 produced sustained GH elevation in healthy adults. Alba et al. (2006, same journal) showed dose-dependent IGF-1 increases. Ipamorelin's selectivity for GH release over cortisol and prolactin has been noted as a potential advantage over older secretagogues like GHRP-6, per Raun et al. (1998, European Journal of Endocrinology).
But here is the catch most social media videos skip: nearly all human trials used very small sample sizes, ran for short durations, and were funded with commercial interests. Long-term safety data in healthy, non-GH-deficient adults essentially does not exist. Neither compound has FDA approval for any indication.
What do physicians promoting these peptides typically get wrong?
The most common error is the safety framing. Calling these compounds "safe" for general use is not supported by the current evidence base. They are not approved drugs. They are not legal for compounding pharmacies under current FDA guidance as of 2024. The FDA removed CJC-1295 and ipamorelin from the list of bulk substances that can be used in compounded preparations.
A second common error is implying these peptides are appropriate for anyone interested in anti-aging or body composition without a diagnosis of growth hormone deficiency. Elevating GH and IGF-1 in people with normal baseline levels is not a well-studied intervention, and IGF-1 elevation has a documented association with increased cancer cell proliferation risk, as reviewed by Pollak (2012, Nature Reviews Cancer).
Third, the "stack" framing, presenting CJC-1295 and ipamorelin as a routine combination, glosses over the fact that combining secretagogues amplifies GH pulses in ways that have not been systematically studied for safety in long-term outpatient use.
What should you actually know before considering these peptides?
Several things that rarely make it into the Instagram version of this conversation.
- Neither CJC-1295 nor ipamorelin is FDA-approved for any condition. Access through compounding pharmacies in the U.S. became significantly restricted after 2023-2024 regulatory actions.
- The populations studied in trials were small and the follow-up periods short. Extrapolating those findings to long-term optimization use in healthy adults is speculative.
- Elevated IGF-1, which both compounds can produce, is not universally beneficial. The relationship between IGF-1 and longevity is complicated: high IGF-1 in midlife has been linked to increased risk of certain cancers, per LeRoith et al. (2021, Endocrine Reviews).
- If you have a diagnosed growth hormone deficiency, there are approved treatments. A physician recommending unapproved peptides instead of or alongside those options owes you a clear explanation of why.
- Side effects reported in trials include fluid retention, joint discomfort, and injection site reactions. They are not trivial for everyone.
The appeal of these peptides is understandable. The marketing is polished, the mechanism sounds clean, and the physicians promoting them often have real credentials. But credentials do not convert an unapproved compound with limited long-term data into a proven safe intervention.